阿曼古丽,吕锡芳,美丽古丽,周小玲,杨宗树.米非司酮对子宫肌瘤剔除术后患者性激素和免疫功能的影响[J].,2017,17(34):6688-6691 |
米非司酮对子宫肌瘤剔除术后患者性激素和免疫功能的影响 |
Effect of Mifepristone on Sex Hormones and Immune Function of Patients with Uterine Fibroid after Myomectomy |
投稿时间:2017-05-16 修订日期:2017-06-14 |
DOI:10.13241/j.cnki.pmb.2017.34.018 |
中文关键词: 子宫肌瘤剔除术 米非司酮 性激素 免疫功能 |
英文关键词: Uterine myomectomy Mifepristone Sex hormones Immune function |
基金项目:新疆维吾尔自治区自然科学基金面上项目(2011211A070) |
|
摘要点击次数: 0 |
全文下载次数: 0 |
中文摘要: |
摘要 目的:探讨子宫肌瘤剔除术后应用米非司酮对患者性激素和免疫功能的影响。方法:选择2013年2月~2015年2月于我院行子宫肌瘤剔除术的患者114例,按抽签法分为对照组与实验组,各57例。对照组行术后常规治疗,实验组基于对照组加以米非司酮治疗。比较两组阴道流血时间,月经恢复时间,雌二醇(E2),孕酮(P),促卵泡生成素(FSH),促黄体生成素(LH),CD3+、CD4+、CD8+,CD4+/CD8+,复发率和不良反应的发生情况。结果:治疗后,实验组阴道流血时间明显短于对照组,且子宫体积小于对照组,实验组月经恢复时间较对照组长,差异有统计学意义(P<0.05);两组E2、P、FSH、LH、CD8+均较治疗前明显下降,且实验组以上指标明显低于对照组,两组CD3+、CD4+、CD4+/CD8+均有明显上升,且实验组以上指标明显高于对照组,差异均有统计学意义(P<0.05)。实验组复发率低于对照组(P<0.05)。两组组不良反应率比较差异无统计学意义(P>0.05)。结论:子宫肌瘤术后应用米非司酮能够降低血清性激素水平,减少复发,且可改善患者的免疫功能。 |
英文摘要: |
ABSTRACT Objective: To research the effect of mifepristone on the sex hormones and immune function of patients with uterine fi- broid after myomectomy. Methods: 114 cases of patients with uterine fibroid after myomectomy admitted in our hospital from February 2013 to February 2015 were selectd and divided into the control group and the experimental group according to the drawing method with 57 cases in each group. The control group was treated with conventional therapy, while the experimental group was given mifepristone based on the control group. The time of vaginal bleeding, menstrual recovery time,estradiol (E2) and progesterone (P), follicle stimulating hormone (FSH), luteinizing hormone (LH), CD3+, CD4+, CD8+, CD4+/CD8+, recurrence rate and incidence of adverse reactions were com- pared between two groups. Results: The bleeding time of experimental group was shorter than that of the control group, and uterine vol- ume of experimental group was lower than that of the control group, the menstruation recovery time of the experimental group was longer than that of the control group(P<0.05). After treatment, the serum E2, P, FSH, LH, CD8+ of both groups were significantly lower than those befroe treatment, which were lower in the experimental group than those of the control group, the CD3+, CD4+, CD4+/CD8+ were significantly higher than those befroe treatment, which were obviously higher in the experimental group than those of the control group(P<0.05). The recurrence rate of experimental group was lower than that of the control group (P<0.05). The incidence of adverse re- action rate of both groups showed no significant difference(P>0.05). Conclusion: Mifepristone could reduce the serum sex hormone levels, avoid recurrence, and improve the immune function of patients with uterine fibroid after myomectomy. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|